AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)
84.71 USD
+0.360 0.427%Sponsored Reports
Loading...
| Previous Close (in USD) | 84.35 |
|---|---|
| Change | +0.360 0.427% |
| 52 W H/L (in USD) | 52.570/15.500 |
| EBITDA (in USD) | -270.007M |
| PE Ratio | -- |
| Volume | 416105 |
| Diluted Eps TTM | -4.63 |
| Total Assets (in USD) | 332.745M |
|---|---|
| Total Liabilities (in USD) | 162.986M |
| Revenue TTM (in USD) | 91.926M |
| Cash (in USD) | 60.081M |
| Market Cap (in USD) | 2,207.829 M |
| Revenue Per Share TTM | 1.571 |
| Gross Profit TTM (in USD) | 21.505M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Employees: 226
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. David P. Meeker M.D. | Chairman, Pres & CEO | 1954 |
| 2. | Mr. Hunter C. Smith M.B.A. | CFO & Treasurer | 1969 |
| 3. | Mr. Joseph Shulman | Chief Technical Officer | 1975 |
| 4. | Mr. Yann Mazabraud | Exec. VP & Head of International | 1973 |
| 5. | Ms. Jennifer L. Chien | Exec. VP & Head of North America | 1975 |
| 6. | Mr. William T. Roberts | Chief Accounting Officer | 1979 |
| 7. | Mr. David Connolly | Head of Investor Relations & Corp. Communications | NA |
| 8. | Mr. Jim Flaherty | Sr. VP & Gen. Counsel | NA |
| 9. | Ms. Sarah Ryan | VP of Sales & Marketing | NA |
| 10. | Ms. Pamela J. Cramer | Chief HR Officer | 1974 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -181.119M | -69.612M | -133.996M | -140.729M | -74.064M |
| Minority Interest | - | - | - | - | - |
| Net Income | -183.081M | -68.007M | -130.727M | -134.624M | -74.064M |
| Selling General Administrative | 92.032M | 68.486M | 46.125M | 36.55M | 28.08M |
| Gross Profit | 21.505M | 2.555M | - | - | 0M |
| Reconciled Depreciation | 1.672M | 1.158M | 0.69M | 0.834M | 0.442M |
| Ebit | -179.157M | -171.217M | -137.265M | -146.834M | -78.859M |
| Ebitda | -175.918M | -170.059M | -136.575M | -146M | -78.417M |
| Depreciation And Amortization | 3.239M | 1.158M | 0.69M | 0.834M | 0.442M |
| Operating Income | -179.157M | -170.059M | -136.575M | -146M | -78.417M |
| Other Operating Expenses | 202.795M | 173.213M | 136.575M | 146M | 78.417M |
| Interest Expense | 5.201M | 100.447M | 0M | 0M | 0M |
| Tax Provision | - | 0M | - | - | - |
| Interest Income | 4.029M | 0.447M | 2.579M | 5.271M | 4.353M |
| Net Interest Income | -1.172M | 0.447M | 2.579M | 5.271M | 4.353M |
| Income Tax Expense | 1.962M | -1.605M | -3.269M | -6.105M | 4.353M |
| Total Revenue | 23.638M | 3.154M | 0M | 0M | 0M |
| Total Operating Expenses | 200.662M | 172.614M | 136.575M | 146M | 78.417M |
| Cost Of Revenue | 2.133M | 0.599M | - | - | 0M |
| Total Other Income Expense Net | -1.962M | 100.447M | 2.579M | 5.271M | 4.353M |
| Net Income From Continuing Ops | -181.119M | -69.612M | -133.996M | -140.729M | -74.064M |
| Net Income Applicable To Common Shares | -181.119M | -69.612M | -133.996M | -140.729M | -74.064M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 332.745M | 382.481M | 329.523M | 187.073M | 308.523M |
| Intangible Assets | 7.028M | 7.883M | 4.658M | - | - |
| Other Current Assets | 6.672M | 11.807M | 12.507M | 8.876M | 9.945M |
| Total Liab | 162.986M | 118.219M | 45.372M | 20.545M | 27.503M |
| Total Stockholder Equity | 169.759M | 264.262M | 284.151M | 166.528M | 281.02M |
| Other Current Liab | 48.262M | 32.894M | 30.084M | 0.18M | 0.377M |
| Common Stock | 0.059M | 0.056M | 0.05M | 0.044M | 0.044M |
| Capital Stock | 0.059M | 0.056M | 0.05M | 0.044M | 0.044M |
| Retained Earnings | -894.736M | -710.058M | -528.939M | -459.327M | -325.331M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 16.983M | 12.143M | 2.21M | 0.403M |
| Cash | 60.081M | 127.677M | 59.248M | 100.854M | 62.294M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 55.203M | 39.809M | 43.427M | 17.994M | 24.417M |
| Current Deferred Revenue | 1.286M | 1.434M | 7M | 12.379M | 13.153M |
| Net Debt | -58.821M | -125.733M | -56.697M | -97.768M | -58.736M |
| Short Term Debt | 0.77M | 0.684M | 0.606M | 0.535M | 0.472M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 1.26M | 1.944M | 2.551M | 3.086M | 3.558M |
| Other Stockholder Equity | 1064.302M | 974.356M | 813.041M | 625.762M | 606.307M |
| Property Plant Equipment | - | 2.197M | 2.813M | 3.195M | 5.716M |
| Total Current Assets | 308.268M | 354.236M | 308.387M | 181.668M | 302.404M |
| Long Term Investments | - | 16.655M | 11.815M | - | - |
| Short Term Investments | 215.765M | 205.611M | 235.607M | 71.938M | 230.165M |
| Net Receivables | 14.867M | 6.224M | 1.025M | - | - |
| Long Term Debt | - | 1.34M | - | - | - |
| Inventory | 8.624M | 2.917M | 0.111M | - | - |
| Accounts Payable | 4.885M | 4.797M | 5.737M | 4.9M | 10.415M |
| Accumulated Other Comprehensive Income | 0.134M | -0.092M | -0.001M | 0.049M | -0.752M |
| Non Currrent Assets Other | 15.327M | 16.983M | 12.143M | 0.403M | 0.403M |
| Non Current Assets Total | 24.477M | 28.245M | 21.136M | 5.405M | 6.119M |
| Capital Lease Obligations | 1.26M | 1.944M | 2.551M | 3.086M | 3.558M |
| Long Term Debt Total | - | 1.34M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 32.31M | -163.725M | 158.745M | -24.585M | -86.426M |
| Total Cashflows From Investing Activities | 28.029M | -62.159M | 158.531M | -27.97M | -87.148M |
| Total Cash From Financing Activities | 213.828M | 166.481M | 2.009M | 163.474M | 164.686M |
| Net Income | -181.119M | -69.612M | -133.996M | -140.729M | -74.064M |
| Change In Cash | 68.429M | -41.681M | 38.56M | 12.754M | 15.482M |
| Begin Period Cash Flow | 59.576M | 101.257M | 62.697M | 49.943M | 34.461M |
| End Period Cash Flow | 128.005M | 59.576M | 101.257M | 62.697M | 49.943M |
| Total Cash From Operating Activities | -173.428M | -146.003M | -121.98M | -122.75M | -62.056M |
| Depreciation | 1.672M | 1.158M | 0.69M | 0.834M | 0.442M |
| Other Cashflows From Investing Activities | -4M | 102M | 95M | -24.585M | -86.426M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -2.806M | -0.011M | -0.011M | -0.011M | - |
| Sale Purchase Of Stock | 141.49M | 166.481M | 2.009M | 163.474M | 164.686M |
| Other Cashflows From Financing Activities | 82.716M | 4.755M | -159.343M | 2.122M | 1.808M |
| Capital Expenditures | 4.281M | 5.434M | 0.214M | 3.385M | 0.722M |
| Change In Working Capital | -19.724M | 1.897M | -5.895M | 5.067M | 0.667M |
| Other Non Cash Items | 5.912M | -0.25M | -0.234M | 0.203M | 4.509M |
| Free Cash Flow | -177.709M | -151.437M | -122.194M | -126.135M | -62.778M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | PRIMECAP Odyssey Aggressive Growth | 2 years ago | 5164410 |
| 2. | PRIMECAP Odyssey Growth | 2 years ago | 2230005 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1881622 |
| 4. | SPDR® S&P Biotech ETF | 2 years ago | 1697711 |
| 5. | Polar Capital Biotech S Inc | 2 years ago | 1500000 |
| 6. | iShares Russell 2000 ETF | 2 years ago | 1244253 |
| 7. | Federated Hermes Kaufmann R | 2 years ago | 840000 |
| 8. | Federated Hermes Kaufmann Growth | 2 years ago | 840000 |
| 9. | Federated Hermes Kaufmann Small Cap A | 2 years ago | 800000 |
| 10. | Federated Hermes Kaufmann Small Cap Grow | 2 years ago | 800000 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 750207 |
| 12. | BlackRock Health Sciences Opps Inv A | 2 years ago | 690347 |
| 13. | BGF World Healthscience A2 | 2 years ago | 660367 |
| 14. | Pictet-Biotech P USD | 2 years ago | 630176 |
| 15. | BlackRock Health Sciences Term Trust | 2 years ago | 580575 |
| 16. | Fidelity Small Cap Index | 2 years ago | 525442 |
| 17. | iShares Russell 2000 Growth ETF | 2 years ago | 450386 |
| 18. | UBS: US Equity Small Cap Growth | 2 years ago | 424131 |
| 19. | Pictet-Global Megatrend Sel I USD | 2 years ago | 406335 |
| 20. | iShares Biotechnology ETF | 2 years ago | 385247 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Goldman Sachs Group Inc | 2 years ago | 10095868 |
| 2. | PRIMECAP Management Company | 2 years ago | 7747591 |
| 3. | Baker Bros Advisors LP | 2 years ago | 6398365 |
| 4. | BlackRock Inc | 2 years ago | 6351750 |
| 5. | RA Capital Management, LLC | 2 years ago | 5330412 |
| 6. | Vanguard Group Inc | 2 years ago | 3304146 |
| 7. | Perceptive Advisors LLC | 2 years ago | 3268579 |
| 8. | NEA Management Company, LLC | 2 years ago | 2909956 |
| 9. | State Street Corporation | 2 years ago | 2206018 |
| 10. | Federated Hermes Inc | 2 years ago | 1661097 |
| 11. | COMMODORE CAPITAL LP | 2 years ago | 1550000 |
| 12. | Rock Springs Capital Management LP | 2 years ago | 1522893 |
| 13. | Polar Capital Holdings PLC | 2 years ago | 1500000 |
| 14. | Pictet Asset Manangement SA | 2 years ago | 1211679 |
| 15. | Driehaus Capital Management LLC | 2 years ago | 855505 |
| 16. | Checkpoint Capital LP | 2 years ago | 825500 |
| 17. | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2 years ago | 730643 |
| 18. | Orbimed Advisors, LLC | 2 years ago | 704842 |
| 19. | HHG PLC | 2 years ago | 621427 |
| 20. | Geode Capital Management, LLC | 2 years ago | 1119129 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...